Bleeding Disorders
News
Fostamatinib approved to treat adults with chronic ITP
The US Food and Drug Administration (FDA) has granted approval for the oral SYK inhibitor fostamatinib disodium hexahydrate (Tavalisse™)....
News
FDA expands approved use of product for VWD
The US Food and Drug Administration (FDA) has expanded the approved use of Vonvendi, a recombinant von Willebrand factor product. Vonvendi is now...
News
Emicizumab receives breakthrough designation
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to emicizumab (Hemlibra®) for patients who have hemophilia...
News
Team modifies platelets to improve coagulation
Researchers say they have found a way to improve the coagulability of platelets—by loading them with thrombin encapsulated in liposomes....
Conference Coverage
Two scoring systems helpful in diagnosing heparin-induced thrombocytopenia
SAN DIEGO – Both the 4Ts Score or the HIT Expert Probability (HEP) Score performed well in a real-world study.
Conference Coverage
Researchers seek better understanding of von Willebrand disease
SAN DIEGO – Researchers are exploring the causes of VWD and ways to tailor treatments.
Conference Coverage
Why is gene therapy for hemophilia taking so long?
SAN DIEGO – The short answer is that gene therapy vectors are complicated.
Conference Coverage
Most patients off transfusions after gene therapy for thalassemia
SALT LAKE CITY – As the vector copy number goes up, so does the likelihood of stopping transfusions.
News
Deaths in patients on emicizumab
Two hemophilia organizations have notified the public of 5 deaths in adult patients receiving emicizumab (Hemlibra). All 5 deaths—occurring in...
Clinical Review
Von Willebrand Disease: Approach to Diagnosis and Management
von Willebrand disease (VWD) is an inherited bleeding disorder caused by deficient or defective plasma von Willebrand factor (VWF). VWF is an...
News
Product approved for hemophilia patients in Japan
Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the bispecific factor IXa- and factor X-directed antibody emicizumab (Hemlibra...